LLY vs PBYI · P/E 39, rev $22.97B vs P/E 4.3, rev $56.5M
Eli Lilly and Company (LLY) versus Puma Biotechnology Inc (PBYI) — a side-by-side from cached financials, not a winner call.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David A. Ricks.
Puma Biotechnology Inc (PBYI) is a biotechnology company listed on US.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Latest reported PBYI revenue for 2026-06-30 was $56.5M. Net income was $8.2M. Revenue was up 26.1% from 2026-03-31 to 2026-06-30. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.
Not investment advice. Open the LLY and PBYI stock pages for the full models.
Not investment advice.